Lapatinib Plus Caelyx in Patients With Advanced Metastatic Breast Cancer Following Failure of Trastuzumab Therapy
Status:
Terminated
Trial end date:
2012-05-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to evaluate the potential of a Lapatinib plus Caelyx combination
therapy as an effective and safe therapeutic regimen with a favourable cardiotoxicity
profile, in the treatment of metastatic breast cancer following failure of prior trastuzumab.